Recruiting

Xanomeline & Trospium ChlorideEvaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Sponsor:

Bristol-Myers Squibb

Code:

NCT07101094

Conditions

Schizophrenia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

xanomeline and trospium chloride (X/T) therapy

Study Details

Brief summary:

The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

Conditions

Schizophrenia

Study ID

NCT07101094

Start date

Sep 22, 2025

Status verified date

Aug, 2026

Completion date

May 14, 2029

Anticipated

Primary completion date

Jan 31, 2029

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Aged ≥18 years at index date.
Have a confirmed diagnosis of schizophrenia before index date.
Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy.
Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines.
Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish).
English or Spanish speaking.

Exclusion Criteria:

Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening.
Evidence of use of XT prior to time of eligibility screening.

Study Design

Enrollment

300 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants receiving xanomeline and trospium chloride (X/T) therapy

Interventions

xanomeline and trospium chloride (X/T) therapy

According to the product label

Primary outcome measure

Participant medication preference as assessed by the Preference of Medication (POM) questionnaire [ Time Frame: Month 1, Month 3, Month 6 ]
Participant treatment satisfaction as assessed by the Medication Satisfaction Questionnaire (MSQ) [ Time Frame: Baseline, Month 1, Month 3, Month 6 ]

Central Contacts and Locations

Central contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 Clinical.Trials@bms.com

Locations

ATP Clinical Research

Recruiting

Costa Mesa, California, United States, 92626

Contacts

Gustavo Alva, Site 0009

949-354-5353

Lumos Clinical Research Center

Recruiting

San Jose, California, United States, 95124

Contacts

Sarbani Maitra, Site 0010

408-668-2712

Evanston Hospital

Recruiting

Evanston, Illinois, United States, 60201

Contacts

Joshua Straus, Site 0003

312-399-3795

The Johns Hopkins Hospital

Recruiting

Baltimore, Maryland, United States, 21287

Contacts

Frederick Nucifora, Site 0007

215-620-3793

Boston Medical Center

Recruiting

Boston, Massachusetts, United States, 02118

Contacts

Hannah Brown, Site 0002

617-638-8141

Mayflower Clinical

Recruiting

South Dartmouth, Massachusetts, United States, 02747

Omaha Insomnia and Psychiatric Services

Recruiting

Omaha, Nebraska, United States, 68144

Contacts

Vithya Selvaraj, Site 0005

402-991-9630

Hackensack Meridian Health - Carrier Clinic

Recruiting

Belle Mead, New Jersey, United States, 08502

Radial - Manhattan

Recruiting

New York, New York, United States, 10018

Contacts

Owen Muir, Site 0015

929-260-5003

New Dawn Psychiatric Services, PLLC

Recruiting

Kinston, North Carolina, United States, 28501

Contacts

Punitha Rathnam, Site 0016

252-686-8091

New Dimension Group

Recruiting

Rose Hill, North Carolina, United States, 28458

Contacts

Constance Olatidoye, Site 0018

910-233-2813

Westlake Brain Health

Recruiting

Westlake, Ohio, United States, 44145

Contacts

Abdelrahman Abdelaziz, Site 0014

317-560-2391

Continuum Health Providers

Recruiting

Fort Mill, South Carolina, United States, 29708

Haracec Clinical Research

Recruiting

El Paso, Texas, United States, 79902

C-Trilogy Outreach

Recruiting

Longview, Texas, United States, 75601

Contacts

Tracy Hicks, Site 0013

903-576-2629

More Information

Sponsor

Bristol-Myers Squibb

Last update posted

Aug 19, 2026

Last verified

Aug, 2026

Keywords

Schizophrenia

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2026-08-19.